Parse Biosciences, a leading provider of scalable single-cell sequencing solutions, has entered into a strategic alliance with bit.bio to develop a comprehensive map of transcription factor-driven cell identity aimed at accelerating predictive drug discovery and therapeutic development. The collaboration seeks to establish a foundational blueprint for creating highly accurate, human-relevant biological models capable of mimicking in vivo cellular responses at scale.

The initiative will focus on understanding how transcription factors regulate both cell state and cell fate using massively parallel causal transcriptomics, an advanced approach that enables researchers to simultaneously analyse thousands of genetic variables to determine the mechanisms driving cellular behaviour.

Under the collaboration, bit.bio will contribute its proprietary opti-ox cell programming technology and Discovery platform, The Cell Foundry, while Parse Biosciences will provide its scalable Evercode single-cell sequencing technology. Together, the companies aim to generate one of the industry’s most extensive datasets linking genetic inputs with biological outputs.

The resulting dataset is expected to guide the development of scalable human cell manufacturing systems, improve therapeutic design and support artificial intelligence models capable of predicting cellular responses to drugs and diseases.

Przemek Obloj, Chief Executive Officer of bit.bio, said that understanding how transcription factors dictate cell fate would help unlock the ‘operating system’ of cells. He noted that the collaboration is designed not only to generate data but also to establish a scalable foundation for predictive AI systems and human-relevant biological models.

Charlie Roco, Co-founder and Chief Technology Officer of Parse Biosciences, said the alliance would create foundational datasets that establish direct causal relationships between genetic changes and biological outcomes, providing critical insights needed for predictive medicine.

bit.bio is recognised for its cell programming technologies designed to create functional human cells and biological models at industrial scale to support drug discovery and the adoption of New Approach Methodologies (NAMs). Parse Biosciences, a Qiagen company, specialises in scalable single-cell sequencing technologies that support research across oncology, regenerative medicine, immunology, and neurological diseases.